Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Brain stem glioma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-16 of 16 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Radiation Therapy in Treating Patients With Recurrent or Progressive Brain Stem Glioma Previously Treated With Radiation Therapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 17 and under
Trial IDs: 2011-0804, NCI-2011-03725, NCT01469247
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Melphalan in Treating Patients with Progressive Diffuse Intrinsic Pontine Gliomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 month to 17 years
Trial IDs: J11164, NCI-2013-00515, NA_00069122, NCT01688401
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Ramucirumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1416, NCI-2015-00744, NCT02564198
Informed Consent to Enroll Younger Patients with Newly Diagnosed Cancer in the Childhood Cancer Research Network
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and under
Trial IDs: ACCRN07, NCI-2009-00331, CDR0000069496, 10-C-0111, NCT01117168
Molecular Profiling in Planning Cancer Treatment in Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 25 and under
Trial IDs: 14082, NCI-2015-01136, 139939, PNOC 003, NCT02274987
Start Over